On October 1st, 2020, Mercodia has launched an updated version of its Glucagon ELISA (Cat.no. 10-1271-01). The update concerns adjustment
to the assay protocol to make certain that even patient samples containing extremely high levels of the proglucagon derivative glicentin give accurate results.
Mercodia is always striving to supply customers with the best assays possible. To this end the company is continuously working with product development and improvement.
The Mercodia Glucagon ELISA was launched in 2013 as a simultaneous protocol. A few years later, when the launch of the
Mercodia Glicentin ELISA made it possible to measure this biomarker accurately, researchers in Cambridge found that extremely high levels of glicentin after bariatric surgery could result in assay interference. Discussions between these researchers and Mercodia led to the development and validation of an alternative sequential protocol for the Mercodia Glucagon ELISA, diminishing this interference. As of October 1st, 2020, this protocol is the default protocol for glucagon measurements using the Mercodia Glucagon ELISA 10-1271-01. The sequential protocol adds an extra washing step to ensure interfering substances are removed; therefore, an additional bottle of buffer is included in the updated version of the Mercodia Glucagon ELISA.
Validation data shows that the Mercodia Glucagon ELISA with the sequential protocol fulfills the requirements for precision, trueness, measuring interval, reference interval, detection capability and analytical specificity. A complete validation report for the updated assay is available upon request.
The updated Mercodia Glucagon ELISA is labeled for IVD (
in-vitro diagnostic) use, so the regulatory status of the assay will not change. It will still be possible to run the “old” simultaneous protocol, but this will no longer be IVD labeled.
Related to:Brands:
MercodiaProduct groups:
Assays